Sancandi Marco, Schul Emma Victoria, Economides Georgia, Constanti Andrew, Mercer Audrey
UCL School of Pharmacy, London, United Kingdom.
Front Cell Neurosci. 2018 Dec 10;12:479. doi: 10.3389/fncel.2018.00479. eCollection 2018.
Early diagnosis of Parkinson's disease (PD) offers perhaps, the most promising route to a successful clinical intervention, and the use of an animal model exhibiting symptoms comparable to those observed in PD patients in the early stage of the disease, may facilitate screening of novel therapies for delaying the onset of more debilitating motor and behavioral abnormalities. In this study, a rat model of pre-motor PD was used to study the etiology of hyposmia, a non-motor symptom linked to the early stage of the disease when the motor symptoms have yet to be experienced. The study focussed on determining the effect of a partial reduction of both dopamine and noradrenaline levels on the olfactory cortex. Neuroinflammation and striking structural changes were observed in the model. These changes were prevented by treatment with a neuroprotective drug, a glucagon-like peptide-1 (GLP1) receptor agonist, exendin-4 (EX-4).
帕金森病(PD)的早期诊断或许为成功的临床干预提供了最具前景的途径,使用一种在疾病早期表现出与PD患者所观察到的症状相似症状的动物模型,可能有助于筛选新的疗法,以延缓更使人衰弱的运动和行为异常的出现。在本研究中,一种运动前帕金森病大鼠模型被用于研究嗅觉减退的病因,嗅觉减退是一种与疾病早期相关的非运动症状,此时运动症状尚未出现。该研究聚焦于确定多巴胺和去甲肾上腺素水平部分降低对嗅觉皮层的影响。在该模型中观察到了神经炎症和显著的结构变化。这些变化通过使用一种神经保护药物、胰高血糖素样肽-1(GLP1)受体激动剂艾塞那肽-4(EX-4)进行治疗得以预防。